Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
0.7288
-0.0241 (-3.20%)
Mar 31, 2025, 2:27 PM EDT - Market open
Vor Biopharma Employees
Vor Biopharma had 159 employees as of December 31, 2024. The number of employees decreased by 9 or -5.36% compared to the previous year.
Employees
159
Change (1Y)
-9
Growth (1Y)
-5.36%
Revenue / Employee
n/a
Profits / Employee
-$735,308
Market Cap
90.99M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 159 | -9 | -5.36% |
Dec 31, 2023 | 168 | 35 | 26.32% |
Dec 31, 2022 | 133 | -2 | -1.48% |
Dec 31, 2021 | 135 | 47 | 53.41% |
Dec 31, 2020 | 88 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
VOR News
- 10 days ago - Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update - GlobeNewsWire
- 6 weeks ago - Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials - GlobeNewsWire
- 2 months ago - Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors - GlobeNewsWire
- 3 months ago - Vor Bio Announces $55.6 Million Private Placement - GlobeNewsWire
- 4 months ago - Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design - GlobeNewsWire
- 6 months ago - Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer - GlobeNewsWire
- 7 months ago - What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday? - Benzinga